Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696770 | 0.89 | EGFR (0.47) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4385924 | 0.85 | ERBB2 (0.48) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4387060 | 0.85 | ERBB2 (0.48) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4389651 | 0.85 | ERBB2 (0.48) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL5490924 | 0.85 | ERBB2 (0.48) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4384923 | 0.85 | ERBB2 (0.48) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4387599 | 0.84 | ERBB2 (0.58) | EGFRERBB2SRCKCNH2 | |
| SCHEMBL4385173 | 0.81 | ERBB2 (0.53) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4387569 | 0.81 | ERBB2 (0.53) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL4490078 | 0.79 | ERBB2 (0.53) | EGFRERBB2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664029-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1664029-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885KDR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.